Trials / Terminated
TerminatedNCT04543279
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet \<50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib | Fostamatinib will be supplied by Rigel Pharmaceuticals. |
| DRUG | Ruxolitinib | Ruxolitinib is commercially available. |
Timeline
- Start date
- 2021-05-03
- Primary completion
- 2022-07-01
- Completion
- 2022-07-30
- First posted
- 2020-09-10
- Last updated
- 2023-12-15
- Results posted
- 2023-12-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04543279. Inclusion in this directory is not an endorsement.